Histotype-specific copy-number alterations in ovarian cancer

[1]  Khay Guan Yeoh,et al.  A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets , 2012, Gut.

[2]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[3]  Kol Jia Yong,et al.  Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours , 2011, Journal of Clinical Pathology.

[4]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[5]  P. Edwards,et al.  Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.

[6]  Razelle Kurzrock,et al.  PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors , 2011, Molecular Cancer Therapeutics.

[7]  P. Dottino,et al.  A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. , 2010, Gynecologic oncology.

[8]  Shun-Fa Yang,et al.  HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target , 2010, Histopathology.

[9]  M. Delorenzi,et al.  Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. , 2010, Cancer research.

[10]  J. Mackey,et al.  Optimizing the management of HER2-positive early breast cancer: the clinical reality. , 2010, Current oncology.

[11]  R. Kurzrock,et al.  Targeted therapy in non-small-cell lung cancer—is it becoming a reality? , 2010, Nature Reviews Clinical Oncology.

[12]  M. A. Pierotti,et al.  Rearrangements of NTRK1 gene in papillary thyroid carcinoma , 2010, Molecular and Cellular Endocrinology.

[13]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[14]  Terence P. Speed,et al.  Identification of Candidate Growth Promoting Genes in Ovarian Cancer through Integrated Copy Number and Expression Analysis , 2010, PloS one.

[15]  C. Runowicz,et al.  The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. , 2010, Gynecologic oncology.

[16]  Anna Adamiak,et al.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy , 2009, BMC Cancer.

[17]  Marit Holden,et al.  Gene Dosage, Expression, and Ontology Analysis Identifies Driver Genes in the Carcinogenesis and Chemoradioresistance of Cervical Cancer , 2009, PLoS genetics.

[18]  Kylie L. Gorringe,et al.  Are there any more ovarian tumor suppressor genes? A new perspective using ultra high‐resolution copy number and loss of heterozygosity analysis , 2009, Genes, chromosomes & cancer.

[19]  D. Carrasco,et al.  BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. , 2009, Cancer research.

[20]  Eun Sung Park,et al.  Identification of potential driver genes in human liver carcinoma by genomewide screening. , 2009, Cancer research.

[21]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[22]  T. Pastor,et al.  [Alterations of c-Myc and c-erbB-2 genes in ovarian tumours]. , 2009, Srpski arhiv za celokupno lekarstvo.

[23]  Lawrence S. Hon,et al.  High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors , 2009, BMC Medical Genomics.

[24]  Laurent Ozbun,et al.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.

[25]  Zachary A. Szpiech,et al.  Genotype, haplotype and copy-number variation in worldwide human populations , 2008, Nature.

[26]  L. Meltesen,et al.  E2A-ZNF384 and NOL1-E2A fusion created by a cryptic t(12;19)(p13.3; p13.3) in acute leukemia , 2008, Leukemia.

[27]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[28]  Ian G. Campbell,et al.  High-Resolution Single Nucleotide Polymorphism Array Analysis of Epithelial Ovarian Cancer Reveals Numerous Microdeletions and Amplifications , 2007, Clinical Cancer Research.

[29]  I. Shih,et al.  Amplicon profiles in ovarian serous carcinomas , 2007, International journal of cancer.

[30]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[31]  J. Ferlay,et al.  Worldwide burden of gynaecological cancer: the size of the problem. , 2006, Best practice & research. Clinical obstetrics & gynaecology.

[32]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[33]  R. Berkowitz,et al.  Whole-Genome Allelotyping Identified Distinct Loss-of-Heterozygosity Patterns in Mucinous Ovarian and Appendiceal Carcinomas , 2005, Clinical Cancer Research.

[34]  P. Marynen,et al.  CIZ gene rearrangements in acute leukemia: report of a diagnostic FISH assay and clinical features of nine patients , 2005, Leukemia.

[35]  R. Fisher.  Statistical methods for research workers , 1927, Protoplasma.

[36]  P. Dessen,et al.  An Atlas on genes and chromosomes in oncology and haematology. , 2004, Cellular and molecular biology.

[37]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[38]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[39]  A. Flanagan,et al.  In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.

[40]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[41]  D. Gisselsson,et al.  A novel fusion gene, SS18L1/SSX1, in synovial sarcoma , 2003, Genes, chromosomes & cancer.

[42]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[43]  J. Melo,et al.  Management of chronic myeloid leukemia: targets for molecular therapy. , 2003, Seminars in hematology.

[44]  P. Marynen,et al.  Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia. , 2002, Cancer research.

[45]  G. V. Ommen,et al.  Medical genomics , 2001, European Journal of Human Genetics.

[46]  P. Nowell,et al.  t(3;11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS (GUANOSINE 5' MONOPHOSPHATE SYNTHETASE) gene. , 2000, Blood.

[47]  K. Cole,et al.  Histopathology and molecular biology of ovarian epithelial tumors. , 1998, Annals of diagnostic pathology.

[48]  G. Chenevix-Trench,et al.  Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. , 1998, Cancer research.

[49]  H. Gabra,et al.  High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. , 1996, British Journal of Cancer.

[50]  W. Foulkes,et al.  Loh and mutation analysis of CDKN2 in primary human ovarian cancers , 1995, International journal of cancer.

[51]  R. Berkowitz,et al.  Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. , 1995, Oncogene.

[52]  M. Inoue,et al.  K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. , 1991, The American journal of pathology.